Influence of trimetazidine on myocardium energy balance during chemotherapy with doxorubicin and cyclophosphamide

Abstract

Aim of the study was to assess the degree of myocardial ischemia in rats on chronic in vivo model, with a simultaneous assessment of justification for the use of trimetazidine. Material and methods. The object of the study was 120 male inbred Wistar rats, randomly divided into 4 equal groups: group 1 – control (administration of 0.9% sodium chloride solution 3 times a week); group 2 – simulation of the AC chemotherapy regimen by intraperitoneal administration of doxorubicin hydrochloride at a single dose of 2.5 mg/kg and cyclophosphamide monohydrate at a single dose of 25 mg/kg 3 times a week; group 3 – simulation of the AC chemotherapy regimen with additional administration of trimetazidine dihydrochloride daily by intragastric gavage at a single dose of 3.0 mg/kg; group 4 – administration of trimetazidine dihydrochloride. The study has been carried out for two weeks. An Olympus IX51 microscope was used to assess the changes. Staining was carried out by the HBFP method (hematoxylin + basic fuchsin + picronic acid). Results and discussion. In group 2, on the background of AC chemotherapy, the level of fuchsinophilia in myocardial tissue was 87.2 and 90.9 % higher (p < 0.05) than in groups 1 and 4, respectively, the specific area of damage was 170.8 and 167. 5 %, respectively (p < 0.05). In group 3, the severity of fuchsinophilia and the specific area of myocardial damage were statistically significantly less (by 26.3 and 36.5 %, p < 0.05) than in group 2. Conclusions. Trimetazidine is a pathogenetically effective drug that protects the myocardium from damage associated with AC chemotherapy.